trending Market Intelligence /marketintelligence/en/news-insights/trending/ZLFiKnjc4DC8lcdKecKBfA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

BioPharmX raising $3.9M from common stock offering to fund pipeline development

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


BioPharmX raising $3.9M from common stock offering to fund pipeline development

BioPharmX Corp. plans to sell 43,645,000 of its common shares at 9 cents apiece to certain institutional investors in a registered direct offering.

The specialty pharmaceutical company said in its March 21 news release that the gross proceeds from the offering are expected to be about $3.9 million.

The net proceeds from the offering will be used to advance the BioPharmX clinical programs, product development and general corporate purposes.

BioPharmX's clinical-stage product candidates include BPX01, which has completed phase 2 studies in treating inflammatory lesions of acne and BPX04, which is in pre-phase 2 feasibility study for the treatment of inflammatory lesions of rosacea, a common skin disease.

The company's clinical-stage assets also includes BPX02, which is being developed for aesthetic dermatology applications and BPX03, which has completed pre-phase 3 study in the treatment of periodic breast pain associated with fibrocystic breast condition, a benign noncancerous condition in which the breasts feel lumpy, and cyclic mastalgia, also known as cyclical breast pain, which is connected to the menstrual cycle and only affects pre-menopausal women.

The offering is expected to close on March 25.

Roth Capital Partners acted as sole placement agent for the offering.

Menlo Park, Calif.-based BioPharmX develops and commercializes novel prescription and over-the-counter products that address dermatology, or skin diseases, and women's health markets.